BKIDC-1553 is an orally available antiglycolytic agent and kinase inhibitor derivative with a predicted half-life of approximately 17 h in humans. BKIDC-1553 inhibits CYP2C8 and angiotensin-converting enzyme and can be used in tumor research.

Physicochemical Properties

Molecular Formula	C22H23N5O2
Molecular Weight	389.45
CAS #	1951431-34-7
Appearance	Solid powder
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	BKIDC-1553 (1.25-20 μM, 72 h) inhibits cell proliferation in a dose-dependent manner in various human prostate cancer cell lines[1].
ln Vivo	BKIDC-1553 (20 mg/kg, orally, 3 times a week for 4 weeks) reduces tumor growth in LuCaP 35 human prostate cancer patient-derived xenograft mice after 5 weeks [1].
References	[1]. A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. bioRxiv [Preprint]. 2024 Feb 13:2023.07.01.547355.

Solubility Data

Solubility (In Vitro)

DMSO : 20 mg/mL (51.35 mM; with sonication)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2 mg/mL (5.14 mM)(saturation unknown) in 10% DMSO 40% PEG300 5% Tween-80 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution This solution produces a clear solution of ≥ 2 mg/mL (saturation unknown). For example, if 1 mL of working solution, add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix well; then add 50 μL Tween-80 to the above system and mix well; then add 450 μL saline to make up to 1 mL. *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (5.14 mM)(saturation unknown) in 10% DMSO 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution This protocol will produce a clear solution of ≥ 2 mg/mL (saturation unknown). . For example, if 1 mL of working solution, add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD in saline and mix well. *Preparation of 20% SBE-β-CD saline solution (4°C, 1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formula 3: ≥ 2 mg/mL (5.14 mM)(saturation unknown) in 10% DMSO 90% Corn Oil (these co-solvents are added from left to right, one by one), clear solution This solution can obtain a clear solution of ≥ 2 mg/mL (saturation unknown). This solution can be used as appropriate for animal experiments with an experimental period of more than half a month. . For example, if you need to prepare 1 mL of working solution, add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.5677 mL	12.8386 mL	25.6772 mL
	5 mM	0.5135 mL	2.5677 mL	5.1354 mL
	10 mM	0.2568 mL	1.2839 mL	2.5677 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.